Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up

Penel, Nicolas; Cesne, Axel Le; Bui, Binh; Pérol, David; Brain, Étienne; Ray‐Coquard, Isabelle; Guillemet, Cécile; Chevreau, Christine; Cupissol, Didier; Chabaud, Sylvie; Jimenez, M. Carolina; Duffaud, Florence; Piperno‐Neumann, Sophie; Mignot, L.; Blay, Jean‐Yves

doi:10.1093/annonc/mdq341

Cited by 207 publications

(144 citation statements)

References 25 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Three single-arm phase ii studies of systemic therapy 16,24,29 serve as the primary evidence base for the recommendations. Spear et al 11 reported that, compared with surgery alone, surgery plus rt led to a higher local control rate at 5 years (72% vs. 69%, p = 0.03).…”

Section: Key Evidencementioning

confidence: 99%

“…In three single-arm phase ii studies, imatinib alone led to a progression-free survival rate of 58% at 3 years 24 and 55% at 2 years, with some grade 3-4 toxicities including rash, neutropenia, myalgia, asthenia, or a secondary cancer (clear cell renal carcinoma) 29 ; and methotrexate plus vinblastine led to a progressionfree survival rate of 67% at 10 years, with 93% of patients developing grade 3 or 4 leukopenia 16 .…”

Section: Key Evidencementioning

confidence: 99%

See 1 more Smart Citation

Treatment and Follow-Up Strategies in Desmoid Tumours: A Practice Guideline

et al. 2014

View full text Add to dashboard Cite

Objectives: We set out to determine the optimal treatment options—surgery, radiation therapy (RT), systemic therapy, or any combinations thereof—for patients with desmoid tumours once the decision to undergo active treatment has been made (that is, monitoring and observation have been determined to be inadequate); provide clinical-expert consensus opinions on follow-up strategies in patients with desmoid tumours after primary interventional management. Methods: This guideline was developed by Cancer Care Ontario’s Program in Evidence-Based Care and the Sarcoma Disease Site Group. The MEDLINE, EMBASE, and Cochrane Library databases, main guideline Web sites, and abstracts of relevant annual meetings (1990 to September 2012) were searched. Internal and external reviews were conducted, with final approval by the Program in Evidence-Based Care and the Sarcoma Disease Site Group. Recommendations: Treatments: Surgery with or without RT can be a reasonable treatment option for patients with desmoid tumours whose surgical morbidity is deemed to be low; The decision about whether RT should be offered in conjunction with surgery should be made by clinicians and patients after weighing the potential benefit of improved local control against the potential harms and toxicity associated with RT; Depending on individual patient preferences, systemic therapy alone or RT alone might also be reasonable treatment options, regardless of whether the desmoid tumours are deemed to be resectable. Follow-Up Strategies: Undergo evaluation for rehabilitation (occupational therapy or physical therapy, or both); Continue with rehabilitation until maximal function is achieved; Undergo history and physical examinations with appropriate imaging every 3–6 months for 2–3 years, and then annually.

show abstract

Section: Key Evidencementioning

confidence: 99%

Section: Key Evidencementioning

confidence: 99%

Treatment and Follow-Up Strategies in Desmoid Tumours: A Practice Guideline

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Radiotherapy was added to the treatment in the present case due to close surgical margins. Non-steroid anti-inflammatory agents (10), and hormonal therapy, also including tamoxifen (11), and imatinib (12), have been recommended in the literature. As the sample from the present case was immunohistochemically stained CD117(+), maintenance imatinib treatment was started upon the completion of radiotherapy, which was consistent with a previous study (12).…”

Section: Discussionmentioning

confidence: 99%

Occurrence of an intrathoracic desmoid tumor following breast cancer treatment: A case report

Değirmencioğlu

Demiray

Yaren

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Desmoid tumors are rarely observed tumors that develop from deep muscle and aponeurotic tissues. They are histologically intermediate, and exhibit a local aggressive course. These tumors have been observed in the abdominal region, and are rarely encountered in the thoracic wall. The most effective treatment appears to be surgery. A 59-year-old female patient was admitted with the complaint of right breast pain and a palpable mass. The patient had undergone a modified radical mastectomy surgical procedure of the right breast due to invasive breast carcinoma 10 years before. A mass with a soft tissue density and a size of 44x22 mm was detected in the thoracic computed tomography of the patient, which subsequently resulted in biopsy followed by surgery. As a result of the pathological examination of the mass, the diagnosis was determined as desmoid tumor. Due to the closeness of the tumor to the surgical margin, the patient was administered radiotherapy and maintenance imatinib treatment was started.

show abstract

“…Study Design and Quality Four articles reported prospective single-arm studies 15,18,23,28 , one was a historical prospective comparative study 31 , and the other twenty-three were retrospective comparative studies (Table ii). Study quality was assessed using the modified Newcastle-Ottawa Scale 51 (detailed table available from the corresponding author).…”

Section: 22mentioning

confidence: 99%

“…Only one retrospective study compared the main clinical characteristics of the patients at baseline, showing no significant differences between the intervention groups 25 ; however, five studies conducted a multivariate analysis to control for potential confounders at baseline [9][10][11]17,22 . Only two studies reported a blinded assessment of outcome 23,28 . The follow-up rates in twenty-three studies exceeded 80%.…”

Section: 22mentioning

confidence: 99%

A Systematic Review of Active Treatment Options in Patients with Desmoid Tumours

et al. 2014

View full text Add to dashboard Cite

show abstract

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up

Abstract: Imatinib is active in the treatment of recurrent and progressive AF/DT, providing objective response and long-term stable disease in a large proportion of patients.

Cited by 207 publications

References 25 publications

Treatment and Follow-Up Strategies in Desmoid Tumours: A Practice Guideline

Treatment and Follow-Up Strategies in Desmoid Tumours: A Practice Guideline

Occurrence of an intrathoracic desmoid tumor following breast cancer treatment: A case report

A Systematic Review of Active Treatment Options in Patients with Desmoid Tumours

Contact Info

Product

Resources

About